Metastatic burden in the liver at endpoint was reduced for both cancer cell types injected with mt-e-CAFs KO HSPG2 compared to mt-e-CAFs WT (Fig. 4j), while mice injected with mt-CCs also developed lung metastases (Supplementary Fig. 5c). The gene discussed is HSPG2; the disease is cancer.